Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024
Rockwell Medical (RMTI) reported strong financial results for Q2 2024, achieving profitability on a cash flow and Adjusted EBITDA basis. Net sales increased 43% to $25.8 million, while gross profit surged 341% to $4.6 million. The company improved its gross margin to 18% from 6% in the same period last year. Notably, Rockwell generated $1.4 million in cash flow from operations.
The company raised its 2024 guidance, now expecting net sales between $95 million and $98 million. Rockwell projects mid-to-high single-digit growth in 2025 and beyond, with gross margins expected to reach above 25% by 2026. The positive results were driven by organic growth in hemodialysis concentrates products, streamlined production, and new customer contracts.
Rockwell Medical (RMTI) ha riportato risultati finanziari solidi per il secondo trimestre del 2024, raggiungendo la redditività in base al flusso di cassa e all'Adjusted EBITDA. Le vendite nette sono aumentate del 43% a 25,8 milioni di dollari, mentre il profitto lordo è schizzato del 341% a 4,6 milioni di dollari. L'azienda ha migliorato il proprio margine lordo, portandolo al 18% rispetto al 6% nello stesso periodo dell'anno scorso. È importante notare che Rockwell ha generato 1,4 milioni di dollari di flusso di cassa dalle operazioni.
L'azienda ha alzato le sue previsioni per il 2024, ora aspettandosi vendite nette comprese tra 95 milioni e 98 milioni di dollari. Rockwell prevede una crescita a una cifra fra il medio e l'alto nel 2025 e oltre, con margini lordi che dovrebbero superare il 25% entro il 2026. I risultati positivi sono stati sostenuti dalla crescita organica nei prodotti concentrati per emodialisi, dalla produzione semplificata e da nuovi contratti con i clienti.
Rockwell Medical (RMTI) reportó resultados financieros sólidos para el segundo trimestre de 2024, logrando rentabilidad en función del flujo de caja y del EBITDA ajustado. Las ventas netas aumentaron un 43% a 25.8 millones de dólares, mientras que el beneficio bruto se disparó un 341% a 4.6 millones de dólares. La compañía mejoró su margen bruto al 18% desde el 6% en el mismo período del año anterior. Notablemente, Rockwell generó 1.4 millones de dólares en flujo de caja de operaciones.
La empresa elevó su guía para 2024, ahora esperando ventas netas entre 95 millones y 98 millones de dólares. Rockwell proyecta un crecimiento de un solo dígito medio a alto en 2025 y más allá, con márgenes brutos que se espera superen el 25% para 2026. Los resultados positivos fueron impulsados por el crecimiento orgánico en productos concentrados de hemodiálisis, la producción optimizada y nuevos contratos de clientes.
록웰 메디컬(RMTI)은 2024년 2분기 강력한 재무 결과를 보고하며, 현금 흐름과 조정 EBITDA 기준으로 수익성을 달성했습니다. 순 매출은 43% 증가하여 2,580만 달러에 달했습니다. 또한 총 이익은 341% 급증하여 460만 달러에 달했습니다. 회사는 지난해 같은 기간의 6%에서 18%로 총 이익률을 개선했습니다. 특히 록웰은 운영에서 140만 달러의 현금 흐름을 생성했습니다.
회사는 2024년 매출 가이드를 상향 조정하여 이제 9,500만 달러에서 9,800만 달러 사이의 순 매출을 예상하고 있습니다. 록웰은 2025년 및 그 이후에 중간에서 높은 단일 자릿수 성장을 예상하며, 2026년까지 총 이익률이 25%를 초과할 것으로 보입니다. 긍정적인 결과는 혈액투석 농축 제품의 유기적 성장, 효율화된 생산 및 신규 고객 계약에 의해 주도되었습니다.
Rockwell Medical (RMTI) a rapporté de solides résultats financiers pour le deuxième trimestre de 2024, atteignant la rentabilité sur une base de flux de trésorerie et d'EBITDA ajusté. Les ventes nettes ont augmenté de 43 % pour atteindre 25,8 millions de dollars, tandis que le bénéfice brut a augmenté de 341 % pour atteindre 4,6 millions de dollars. L'entreprise a amélioré sa marge brute à 18 % contre 6 % au cours de la même période l'année dernière. Il est à noter que Rockwell a généré 1,4 million de dollars de flux de trésorerie provenant des opérations.
L'entreprise a relevé ses prévisions pour 2024, espérant désormais un chiffre d'affaires net compris entre 95 millions et 98 millions de dollars. Rockwell prévoit une croissance à un chiffre, moyenne à élevée, en 2025 et au-delà, avec des marges brutes qui devraient dépasser 25 % d'ici 2026. Les résultats positifs ont été propulsés par une croissance organique des produits concentrés pour hémodialyse, une production rationalisée et de nouveaux contrats de clients.
Rockwell Medical (RMTI) hat starke finanzielle Ergebnisse für das zweite Quartal 2024 vorgestellt und dabei Rentabilität auf Basis des Cashflows und des bereinigten EBITDA erzielt. Der Nettoumsatz stieg um 43% auf 25,8 Millionen Dollar, während der Bruttogewinn um 341% auf 4,6 Millionen Dollar anstieg. Das Unternehmen verbesserte seine Bruttomarge auf 18% von 6% im gleichen Zeitraum des Vorjahres. Bemerkenswert ist, dass Rockwell 1,4 Millionen Dollar Cashflow aus dem operativen Geschäft generiert hat.
Das Unternehmen hat seine Prognose für 2024 angehoben und erwartet nun einen Nettoumsatz von 95 Millionen bis 98 Millionen Dollar. Rockwell rechnet mit einem mittleren bis hohen einstelligen Wachstum im Jahr 2025 und darüber hinaus, wobei die Bruttomargen voraussichtlich bis 2026 über 25% steigen werden. Die positiven Ergebnisse wurden durch organisches Wachstum der Produkte für Hämodialysekonzentrate, optimierte Produktion und neue Kundenverträge angetrieben.
- Net sales increased 43% year-over-year to $25.8 million in Q2 2024
- Gross profit surged 341% to $4.6 million in Q2 2024
- Gross margin improved to 18% from 6% in the same period last year
- Generated $1.4 million in cash flow from operations in Q2 2024
- Achieved profitability on a cash flow and Adjusted EBITDA basis
- Raised 2024 net sales guidance to $95-$98 million
- Projects mid-to-high single-digit growth in 2025 and beyond
- Expects gross margins to reach above 25% by 2026
- None.
Insights
Rockwell Medical's Q2 2024 results show significant improvement, marking a turning point towards profitability. Key highlights include:
- Net sales up
43% YoY to$25.8 million - Gross profit surged
341% to$4.6 million - Gross margin improved from
6% to18% - Positive cash flow of
$1.4 million from operations
The company's focus on its hemodialysis concentrates business is paying off, with organic growth driving performance. The raised guidance for 2024, projecting sales between
Rockwell's strategic pivot to focus on its hemodialysis products is yielding positive results. The launch of the Convenience Pack for home patients and acute facilities demonstrates innovation in meeting market needs. The company's efforts to upgrade manufacturing equipment and renegotiate supplier contracts are contributing to margin improvements.
The hemodialysis market is growing due to increasing prevalence of chronic kidney disease. Rockwell's projected mid-to-high single-digit growth beyond 2024 and expected gross margin expansion to
Rockwell's turnaround strategy is showing promising results. The focus on core competencies in hemodialysis products has streamlined operations and improved financial performance. Key strategic moves include:
- Upgrading manufacturing for efficiency
- Renegotiating supplier contracts
- Expanding customer base
- Launching innovative products like the Convenience Pack
The amendment to the Evoqua agreement, extending payment schedules and reducing payments, demonstrates prudent financial management. However, the company must balance growth investments with maintaining its newfound profitability. The projected gross margin expansion to
-
Reports net sales of
$25.8 million 43% over the same period in 2023. -
Reports gross profit of
$4.6 million 341% over the same period in 2023. -
Achieves gross margin of
18% for the second quarter of 2024 compared to a gross margin of6% for the same period in 2023. -
Generates
$1.4 million -
Expects net sales for 2024 to range between
$95 million $98 million
"Over the past two years, we have been relentless in our determination to put Rockwell Medical in a stronger and more stable financial position that ultimately has the potential to positively impact more patients," said Mark Strobeck, Ph.D., Rockwell Medical’s President and CEO. "We achieved profitability on a cash flow basis, which we believe is a turning point for our organization. We expect to build upon this momentum in the coming quarters."
SECOND QUARTER 2024 FINANCIAL HIGHLIGHTS
Net sales for the three and six months ended June 30, 2024 consisted solely of concentrates products sales. Net sales for the three and six months ended June 30, 2023 consisted of sales of concentrates products and the recognition of
-
Net sales for the three months ended June 30, 2024 were
$25.8 million 43% increase over net sales of$18.1 million $48.5 million 29% increase over net sales of$37.7 million 34% over the same period in 2023. -
Gross profit for the three months ended June 30, 2024 was
$4.6 million 341% increase over$1.0 million $7.6 million 110% increase over$3.6 million 252% over the same period in 2023. -
Gross margin for the three months ended June 30, 2024 was
18% , which represents an increase from6% for the same period in 2023. Gross margin for the six months ended June 30, 2024 was16% , which represents an increase from10% , or6% excluding deferred revenue, for the same period in 2023. -
Net income for the three months ended June 30, 2024 was
$0.3 million $3.3 million $3.7 million $5.1 million $5.1 million $6.5 million -
Adjusted EBITDA for the three months ended June 30, 2024 was
$1.5 million $2.3 million $1.0 million $3.2 million $5.7 million -
Cash and cash equivalents and investments available-for-sale at June 30, 2024 increased to
$11.9 million $1.4 million $8.6 million - Subsequent to the second quarter of 2024, Rockwell Medical and Evoqua Water Technologies LLC (“Evoqua”) executed an amendment to the Asset Purchase Agreement dated July 10, 2023, which clarifies certain terms regarding physical assets covered by the purchase agreement between the two companies, provides for an extended payment schedule for the deferred payments due by the Company to Evoqua, and provides for a partial reduction in such payments.
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
(In Millions, Except Per Share Amounts) |
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
2023* |
||
Net Sales |
$ |
25.8 |
|
$ |
18.1 |
|
|
$ |
48.5 |
|
|
$ |
37.7 |
|
|
|
|
|
|
|
|
|
|
||||||||
Gross Profit (Loss) |
|
4.6 |
|
|
1.0 |
|
|
|
7.6 |
|
|
|
3.6 |
|
|
|
|
|
|
|
|
|
|
||||||||
Operating Income (Loss) |
|
0.5 |
|
|
(3.0 |
) |
|
|
(0.8 |
) |
|
|
(4.4 |
) |
|
Net Income (Loss) |
|
0.3 |
|
|
(3.3 |
) |
|
|
(1.4 |
) |
|
|
(5.1 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA** |
|
1.5 |
|
|
(2.3 |
) |
|
|
1.0 |
|
|
|
(3.2 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Basic and Diluted Net Income (Loss) per Share ** |
$ |
0.01 |
|
$ |
(0.18 |
) |
|
$ |
(0.05 |
) |
|
$ |
(0.27 |
) |
|
|
|
|
|
|
|||||||||||
Adjusted EPS *** |
$ |
0.05 |
$ |
(0.12 |
) |
$ |
0.03 |
|
$ |
(0.18 |
) |
||||
* |
Includes |
** |
See Note 3 for more details related to Basic and Diluted Weighted Average Shares Outstanding on Form 10-Q filed August 8, 2024. |
*** |
See reconciliation to GAAP financial measures in the tables below. |
SECOND QUARTER 2024 OPERATING HIGHLIGHTS
- Rockwell Medical promoted Tim Chole to Chief Commercial Officer. Mr. Chole joined Rockwell Medical in December 2019 as SVP, Sales and Marketing. In November 2022, following the Company's new business strategy announcement, Mr. Chole led Rockwell's commercial organization and supported the Company's vision to focus its efforts on enhancing its revenue-generating businesses and driving the Company towards profitability.
- Rockwell Medical maintained its membership on the Russell Microcap® Index for the second year in a row. FTSE Russell determines membership for its Russell indexes primarily by objective, market capitalization rankings and style attributes.
- Rockwell Medical continues to upgrade its manufacturing equipment to streamline production and improve margins; renegotiate contracts with key suppliers; and negotiate new contracts with new customers.
- Rockwell Medical launched its Convenience Pack, which includes two 1-gallon pre-mixed containers of one of the Company's hemodialysis concentrate products RenalPure or SteriLyte, offering a number of advantages for home patients and acute facilities.
GUIDANCE
Rockwell Medical updates its 2024 guidance as follows:
|
Updated
|
Updated
|
Original
|
Net (Product) Sales |
|
|
|
Gross Profit |
|
|
|
Gross Margin |
|
|
|
Adjusted EBITDA |
|
|
|
Rockwell Medical projects net sales to grow in the mid-to-high single digits in 2025 and beyond. Rockwell Medical projects gross margin in 2025 to be approximately
CONFERENCE CALL AND WEBCAST DETAILS
Date: Thursday, August 8, 2024
Time: 8:00am ET
Live Number: (888) 660-6347 // (International) 1 (929) 201-6594
Conference Call ID: 4944610
Webcast and Replay: www.RockwellMed.com/Results
Speakers:
- Mark Strobeck, Ph.D. — President and Chief Executive Officer; and
- Jesse Neri — SVP, Finance.
Format: Discussion of second quarter 2024 financial and operational results followed by Q&A.
NON-GAAP FINANCIAL MEASURES
To supplement Rockwell Medical’s unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in
Adjusted EBITDA is a key measure used by Rockwell Medical to understand and evaluate operating performance and trends, to prepare and approve its annual budget and to develop short- and long-term operating plans. The Company provides Adjusted EBITDA because it believes the metric is helpful in highlighting trends in its operating results because it excludes items that are not indicative of Rockwell Medical’s core operating performance. In particular, the Company believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of Rockwell Medical’s business. Adjusted net sales, gross profit, gross margin and net loss is used by Rockwell Medical to understand growth within its hemodialysis concentrates business by excluding a one-time item that is not indicative of its core operating performance.
Adjusted EBITDA and net sales, gross profit, gross margin, net income, and net loss should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA and adjusted net sales, gross profit, gross margin and net loss as tools for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than the most directly comparable financial measures calculated in accordance with GAAP. When evaluating the Company’s performance, you should consider Adjusted EBITDA and adjusted net sales, gross profit, gross margin and net loss alongside other financial performance measures, including net loss and other GAAP results. Adjusted EBITDA is our best proxy for cash burn. Adjusted net sales, gross profit, gross margin and net loss enable us to understand growth within our hemodialysis concentrates business by excluding a one-time item that is not indicative of our core operating performance.
ABOUT ROCKWELL MEDICAL
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at freestanding outpatient dialysis centers, at hospital-based outpatient centers, at skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the largest supplier of liquid bicarbonate concentrates and the second largest supplier of acid and dry bicarbonate concentrates for dialysis patients in
FORWARD-LOOKING STATEMENTS
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “feel confident,” “guidance,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include (without limitation) statements regarding: plans to expand our global footprint; the impact of our strategy on our top and bottom line and building upon our financial results; the growth of our business; the impact of attaining profitability on the trajectory of our business; guidance for expenses, net sales, gross profit, gross margin and adjusted EBITDA. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any subsequent reports filed with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
Financial Tables Follow
| ROCKWELL MEDICAL, INC. AND SUBSIDIARIES | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (Dollars In Thousands) | ||||||
| June 30, | June 30, | |||||
2024 |
2023 |
|||||
| Cash, Cash Equivalents & Investments available-for-sale | $ |
11,863 |
$ |
14,865 |
||
| Total Assets | $ |
53,028 |
$ |
38,037 |
||
| Total Liabilities | $ |
29,530 |
$ |
28,509 |
||
| Total Stockholders’ Equity | $ |
23,498 |
$ |
9,528 |
||
| Common Stock Outstanding |
|
31,030,218 |
|
18,588,673 |
||
| Common stock and common stock equivalents* |
|
38,808,569 |
|
32,033,132 |
||
| *Common stock and common stock equivalents: | ||||||
| Common stock |
|
31,030,218 |
|
16,795,673 |
||
| Common stock warrants (pre-funded) |
|
- |
|
1,793,000 |
||
| Common stock and pre-funded stock warrants |
|
31,030,218 |
|
18,588,673 |
||
| Preferred stock converted |
|
1,363,636 |
|
1,363,636 |
||
| Options to purchase common stock |
|
1,895,031 |
|
1,570,599 |
||
| Restricted stock awards |
|
891 |
|
891 |
||
| Restricted stock units |
|
534,309 |
|
313,065 |
||
| Common stock warrants |
|
3,984,484 |
|
10,196,268 |
||
| Total common stock and common stock equivalents |
|
38,808,569 |
|
32,033,132 |
||
| ROCKWELL MEDICAL, INC. AND SUBSIDIARIES | |||||||||||||||
| UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
| (In Thousands, Except Shares and Per Share Amounts) | |||||||||||||||
| Three Months Ended June 30, 2024 |
Three Months Ended June 30, 2023 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
||||||||||||
| Net Sales | $ |
25,832 |
|
$ |
18,080 |
|
$ |
48,508 |
|
$ |
37,748 |
|
|||
| Cost of Sales |
|
21,282 |
|
|
17,047 |
|
|
40,894 |
|
|
34,116 |
|
|||
| Gross Profit |
|
4,550 |
|
|
1,033 |
|
|
7,614 |
|
|
3,632 |
|
|||
| Research and Product Development |
|
- |
|
|
167 |
|
|
18 |
|
|
445 |
|
|||
| Selling and Marketing |
|
586 |
|
|
530 |
|
|
1,180 |
|
|
1,028 |
|
|||
| General and Administrative |
|
3,449 |
|
|
3,295 |
|
|
7,225 |
|
|
6,545 |
|
|||
| Operating Income (Loss) |
|
515 |
|
|
(2,959 |
) |
|
(809 |
) |
|
(4,386 |
) |
|||
| Other (Expense) Income | |||||||||||||||
| Realized Gain on Investments |
|
51 |
|
|
- |
|
|
51 |
|
|
- |
|
|||
| Interest Expense |
|
(232 |
) |
|
(395 |
) |
|
(663 |
) |
|
(782 |
) |
|||
| Interest Income |
|
9 |
|
|
49 |
|
|
33 |
|
|
113 |
|
|||
| Total Other Expense |
|
(172 |
) |
|
(346 |
) |
|
(579 |
) |
|
(669 |
) |
|||
| Net Income (Loss) | $ |
343 |
|
$ |
(3,305 |
) |
$ |
(1,388 |
) |
$ |
(5,055 |
) |
|||
| Basic Net Income (Loss) per Share | $ |
0.01 |
|
$ |
(0.18 |
) |
$ |
(0.05 |
) |
$ |
(0.27 |
) |
|||
| Basic Weighted Average Shares Outstanding |
|
30,451,622 |
|
|
18,496,640 |
|
|
29,889,413 |
|
|
18,480,248 |
|
|||
| Reconciliation to GAAP Financial Measures | |||||||||||||||
| (In Thousands, Except Shares and Per Share Amounts) | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30 | June 30 | ||||||||||||||
|
2024 |
|
2023 |
|
|
2024 |
|
|
2023 |
|
|||||
| Net Income (Loss) | $ |
343 |
$ |
(3,305 |
) |
$ |
(1,388 |
) |
$ |
(5,055 |
) |
||||
| Income taxes | |||||||||||||||
| Interest expense |
|
232 |
|
395 |
|
|
663 |
|
|
782 |
|
||||
| Depreciation and amortization |
|
548 |
|
169 |
|
|
1,092 |
|
|
328 |
|
||||
| EBITDA |
|
1,123 |
|
(2,741 |
) |
|
367 |
|
|
(3,945 |
) |
||||
| Severance costs |
|
9 |
|
171 |
|
|
9 |
|
|
201 |
|
||||
| Stock-based compensation |
|
338 |
|
312 |
|
|
589 |
|
|
505 |
|
||||
| Adjusted EBITDA | $ |
1,470 |
$ |
(2,258 |
) |
$ |
965 |
|
$ |
(3,239 |
) |
||||
| Adjusted EPS | $ |
0.05 |
$ |
(0.12 |
) |
$ |
0.03 |
|
$ |
(0.18 |
) |
||||
| Basic Weighted Average Shares Outstanding |
|
30,451,622 |
|
18,496,640 |
|
|
29,889,413 |
|
|
18,480,248 |
|
||||
| Reconciliation to GAAP Financial Measures | |||||||||||||||
| (Dollars in Thousands) | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30 | June 30 | ||||||||||||||
|
2024 |
|
2023 |
|
|
2024 |
|
|
2023 |
|
|||||
| Net Sales | $ |
25,832 |
$ |
18,080 |
|
$ |
48,508 |
|
$ |
37,748 |
|
||||
| Deferred Revenue |
|
- |
|
- |
|
|
- |
|
|
(1,472 |
) |
||||
| Net Sales excluding Deferred Revenue |
|
25,832 |
|
18,080 |
|
|
48,508 |
|
|
36,276 |
|
||||
| Gross Profit |
|
4,550 |
|
1,033 |
|
|
7,614 |
|
|
3,632 |
|
||||
| Deferred Revenue |
|
- |
|
- |
|
|
- |
|
|
(1,472 |
) |
||||
| Gross Profit excluding Deferred Revenue | $ |
4,550 |
$ |
1,033 |
|
$ |
7,614 |
|
$ |
2,160 |
|
||||
| Net Income (Loss) |
|
343 |
|
(3,305 |
) |
|
(1,388 |
) |
|
(5,055 |
) |
||||
| Deferred Revenue |
|
- |
|
- |
|
|
- |
|
|
(1,472 |
) |
||||
| Net Income (Loss) excluding Deferred Revenue | $ |
343 |
$ |
(3,305 |
) |
$ |
(1,388 |
) |
$ |
(6,527 |
) |
||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808643432/en/
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@RockwellMed.com
Source: Rockwell Medical, Inc.
FAQ
What was Rockwell Medical's (RMTI) net sales growth in Q2 2024?
How much cash flow from operations did RMTI generate in Q2 2024?
What is Rockwell Medical's (RMTI) updated net sales guidance for 2024?
How did RMTI's gross margin improve in Q2 2024 compared to Q2 2023?
